Montelukast Paediatric Aurobindo Pharma (Malta) (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes such as LTC4, LTD4, and LTE4 from binding. By inhibiting these inflammatory mediators, it reduces bronchial smooth‑muscle contraction, mucus secretion, and vascular leakage that contribute to asthma and allergic rhinitis.

The appropriate dose of Montelukast Paediatric is determined by the prescribing clinician based on the child’s age, weight, and specific condition. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for optimal control.

Safety data for Montelukast in pregnancy and lactation are limited. The prescriber should weigh potential benefits against risks and consider alternative therapies when possible. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients with allergic components or those who experience exercise‑induced bronchoconstriction, but it is generally used as an add‑on rather than a sole replacement for inhaled steroids.

Montelukast Paediatric should be stored below 25 °C in a dry place. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually as a chewable tablet or oral suspension, as directed by the prescriber. It is typically given once daily in the evening, but the exact timing and method are determined by the treating clinician.

Serious risks include rare allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric events like mood changes, depression, or suicidal thoughts. Patients and caregivers should seek immediate medical attention if any severe or unexpected symptoms develop.

Montelukast Paediatric is contraindicated in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is advised for children with severe hepatic impairment, and the drug should be avoided in patients who have experienced serious allergic reactions to leukotriene‑modifying agents.